{"id":"smc-with-sp-aq","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1945534","moleculeType":"Small molecule","molecularWeight":"5841.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination therapy uses two antimalarial agents with complementary mechanisms: sulfadoxine-pyrimethamine inhibits dihydrofolate reductase and dihydropteroate synthase in the malaria parasite, while amodiaquine acts as a quinoline antimalarial. Administered as intermittent preventive treatment during peak malaria transmission seasons, the regimen provides sustained protection by maintaining therapeutic drug levels that suppress parasitemia and prevent clinical malaria episodes in vulnerable pediatric populations.","oneSentence":"SMC with SP+AQ is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine and amodiaquine to prevent malaria infection in children during high-transmission seasons.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:01.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal malaria chemoprevention in children aged 3-59 months in sub-Saharan Africa during high-transmission seasons"}]},"trialDetails":[{"nctId":"NCT07281443","phase":"NA","title":"MDA and Targeted Control Against Plasmodium Carriage in the Sahel","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherche pour le Developpement","startDate":"2024-09-23","conditions":"Malaria, Falciparum, Malaria, Asymptomatic Parasitaemia","enrollment":18000},{"nctId":"NCT05878366","phase":"NA","title":"Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-07-13","conditions":"Malaria, Malaria,Falciparum","enrollment":2978},{"nctId":"NCT06225297","phase":"PHASE4","title":"Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal","status":"SUSPENDED","sponsor":"PATH","startDate":"2024-01-19","conditions":"Malaria","enrollment":4600},{"nctId":"NCT04319380","phase":"PHASE3","title":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ) Extension Study","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2020-04-01","conditions":"Malaria,Falciparum, Child, Only","enrollment":5098},{"nctId":"NCT06337253","phase":"PHASE4","title":"Seasonal Malaria Chemoprevention Rapid Assessment Study Mozambique","status":"NOT_YET_RECRUITING","sponsor":"Malaria Consortium","startDate":"2024-03-26","conditions":"Malaria,Falciparum, Chemoprevention","enrollment":1000},{"nctId":"NCT06182176","phase":"NA","title":"Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control","status":"UNKNOWN","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2024-05-27","conditions":"Malaria, Soil Transmitted Helminths, Schistosomiasis","enrollment":1200},{"nctId":"NCT04969185","phase":"","title":"Association Between Drug Levels, Malaria, and Antimalarial Resistance in the Setting of Seasonal Malaria Chemoprevention","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-08-16","conditions":"Malaria,Falciparum","enrollment":310},{"nctId":"NCT03143218","phase":"PHASE3","title":"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2017-04-17","conditions":"Malaria,Falciparum, Children, Only","enrollment":5920}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SMC with SP+AQ","genericName":"SMC with SP+AQ","companyName":"London School of Hygiene and Tropical Medicine","companyId":"london-school-of-hygiene-and-tropical-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SMC with SP+AQ is a seasonal malaria chemoprevention regimen combining sulfadoxine-pyrimethamine and amodiaquine to prevent malaria infection in children during high-transmission seasons. Used for Seasonal malaria chemoprevention in children aged 3-59 months in sub-Saharan Africa during high-transmission seasons.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}